查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362945

北美尿道感染檢測（UTI 檢測）市場規模、佔有率和趨勢分析報告：2023-2030 年按類型、按產品、最終用途、國家和細分市場分類的趨勢

North America Urinary Tract Infection Testing Market Size, Share & Trends Analysis Report By Type, By Product, By End-use, By Country, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

北美尿道感染檢測（UTI檢測）市場成長與趨勢：

Grand View Research, Inc. 的一項新研究顯示，到 2030 年，北美 UTI 檢測市場規模預計將達到 2.6916 億美元。

預計 2023 年至 2030 年該市場將以 4.0% 的年複合成長率擴張。由於該地區政府控制泌尿道感染的舉措不斷增加、尿路感染檢測技術的進步以及高度發達的醫療基礎設施和醫療設施的普及，該地區尿路感染檢測市場正在不斷成長。例如，根據《紐約時報》2019 年 7 月發表的報導，紐約市衛生部推出了一款對抗抗藥性泌尿道感染的行動應用程式。該應用程式為醫生和護士提供了感染菌株和對某些藥物的抗藥性的清單。

衛生部進行的研究表明，許多由大腸桿菌（最常見的類型）引起的尿道結石對廣泛使用的藥物（例如 Bactrim）具有抗藥性。人們對抗藥性尿道結石的日益關注正在推動北美地區對先進尿路感染檢測解決方案的需求。醫療保健提供者正在尋求更精確、更有針對性的治療方法，以應對日益嚴重的抗生素抗藥性問題。因此，該地區的尿路感染檢測市場正在經歷顯著成長。

結合創新診斷技術可以顯著增強患者照護和管理，同時透過更快的結果交付促進抗生素管理，推動市場成長。例如，由美國工程師和分子生物學家組成的團隊開發了一種具有成本效益的即時診斷測試，可以快速檢測尿液中的微生物病原體。該設備使用簡單的實驗室套件、LED 燈、熱板和智慧型手機，在資源有限的環境中顯示出快速、低成本診斷尿路感染的巨大潛力。

北美尿路感染檢測市場報告亮點

  • 整體市場的成長歸因於該地區人口中尿路感染的患病不斷上升。
  • 隨著對技術先進的居家照護道感染檢測套組的需求不斷增加，泌尿道感染檢測市場正在發生重大變化。
  • 由於膀胱炎患者的發生率和復發率較高，2022年膀胱炎佔最大的市場佔有率，為41.41%。
  • 設備部門市場佔據主導地位，2022年銷售佔有率為60.36%。這是因為診斷技術的進步促進了功能增強的先進設備的開發。
  • 以最終用途，參考實驗室領域在 2022 年佔據最大銷售佔有率，達到 26.11%。這是由於這些實驗室提供了廣泛的綜合測試服務。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章 北美UTI檢測市場：類型分析

  • 北美UTI測試市場：類型變異分析
  • 尿道炎
  • 膀胱炎
  • 腎盂腎炎

第5章 北美UTI檢測市場：產品分析

  • 北美UTI測試市場：產品變化分析
  • 裝置
  • 消耗品

第6章 北美 UTI 測試市場：最終用途分析

  • 北美 UTI 測試市場：最終用途變化分析
  • 全科醫生
  • 泌尿系統
  • 泌尿婦科醫生
  • 醫院實驗室
  • 參考實驗室
  • 醫院急診部門
  • 緊急護理
  • 其他

第7章 北美UTI檢測市場：區域分析

  • 北美洲

第8章 競爭形勢

  • 參與企業
    • QIAGEN
    • Accelerate Diagnostics, Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Danaher Corporation
    • Siemens Healthcare GmbH
    • Randox Laboratories Ltd.
    • Thermo Fisher Scientific, Inc.
    • bioMerieux SA
    • T2 Biosystems, Inc.
  • 參與企業概況
  • 財務實績
  • 產品基準評效
  • 2022 年公司市場佔有率分析
  • 策略規劃
    • 擴張
    • 收購
    • 產品/服務發布
    • 其他

第9章 結論/分析師的觀點

Product Code: GVR-4-68040-113-0

North America Urinary Tract Infection Testing Market Growth & Trends:

The North America urinary tract infection testing market size is expected to reach USD 269.16 million by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 4.0% from 2023 to 2030. The regional UTI testing market is growing due to increasing government initiatives regarding UTI control in the region, technological advancements in UTI testing, and highly developed healthcare infrastructure & improved access to healthcare facilities. For instance, an article published by The New York Times in July 2019 mentioned that the New York City Department of Health launched a mobile app to address drug-resistant urinary tract infections (UTIs). The app provides doctors and nurses with a list of infection strains and their resistance to specific drugs.

Research conducted by this department revealed that many of the UTIs caused by E. coli, the most common type, were resistant to widely used drugs like Bactrim. This growing concern over drug-resistant UTIs drives the demand for advanced UTI testing solutions in North America, as healthcare providers seek more accurate and targeted therapies to combat the rising issue of antibiotic resistance. As a result, the UTI testing market in the region is experiencing significant growth.

Incorporating innovative diagnostic technologies can significantly enhance patient care and management while promoting antibiotic stewardship through faster result delivery, thereby driving market growth. For instance, a team of engineers and molecular biologists in the U.S. has developed a cost-effective point-of-care diagnostic test for rapidly detecting microbial pathogens in urine. Using a simple lab kit, LED lights, a hot plate, and a smartphone, the device shows promising potential for quick and low-cost diagnosis of urinary tract infections (UTIs) in resource-limited settings.

Furthermore, a pilot study published in eBioMedicine compared the smartphone-based real-time loop-mediated isothermal amplification (smaRT-LAMP) system to the more expensive rapid diagnostic technologies and standard hospital tests. The results demonstrated that the smaRT-LAMP system matched the accuracy of hospital diagnostics while significantly reducing costs and testing time.

Key players in the regional urinary tract infection testing market, such as F. Hoffmann-La Roche Ltd., bioMerieux SA, T2 Biosystems, Abbott, Siemens Healthcare GmbH, etc., are implementing strategic initiatives such as mergers, acquisitions, and collaborations to enhance product capabilities and promote their offerings. For instance, in November 2022, Illumina, a global leader in DNA sequencing and array-based technologies, introduced the Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP). This research test utilizes precision metagenomics to identify and measure genitourinary pathogens, including drug-resistant ones that lead to complicated and recurrent urinary tract infections (UTIs).

North America Urinary Tract Infection Testing Market Report Highlights:

  • The growth of the overall market is attributed to the increasing prevalence of UTIs among the population in the region
  • The UTI testing market is witnessing a key shift with the rise in demand for technologically advanced homecare UTI testing kits
  • Cystitis held the largest market share of 41.41% in 2022, owing to the high incidence & recurrence rate of cystitis in patients
  • The instruments segment dominated the market with a revenue share of 60.36% in 2022. This is attributed to advancements in diagnostic technologies that have led to the development of sophisticated instruments with enhanced capabilities
  • Based on end-use, the reference laboratories segment accounted for the largest revenue share of 26.11% in 2022. This is attributed to the wide range of comprehensive testing services offered by these laboratories

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type segment
      • 1.1.1.2. Product segment
      • 1.1.1.3. End-user segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Type Snapshot
  • 2.3. End-use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of urinary tract infections (UTIs)
      • 3.2.1.2. Technological Advancements in Urinary Tract Infection Testing
      • 3.2.1.3. Growing prevalence of catheter-associated UTIs (CAUTIs)
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost associated with advanced UTI testing technologies.
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Urinary Tract Infection Testing Market: Type Analysis

  • 4.1. North America Urinary Tract Infection Testing Market: Type Movement Analysis
  • 4.2. Urethritis
    • 4.2.1. Urethritis Market, 2018 - 2030 (USD Million)
  • 4.3. Cystitis
    • 4.3.1. Cystitis Market, 2018 - 2030 (USD Million)
  • 4.4. Pyelonephritis
    • 4.4.1. Pyelonephritis Market, 2018 - 2030 (USD Million)

Chapter 5. North America Urinary Tract Infection Testing Market: Product Analysis

  • 5.1. North America Urinary Tract Infection Testing Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. Instruments Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 5.3. Consumables
    • 5.3.1. Consumables Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

Chapter 6. North America Urinary Tract Infection Testing Market: End-use Analysis

  • 6.1. North America Urinary Tract Infection Testing Market: End-use Movement Analysis
  • 6.2. General Practitioners
    • 6.2.1. General Practitioners Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.3. Urologists
    • 6.3.1. Urologists Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.4. Urogynecologists
    • 6.4.1. Urogynecologists Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.5. Hospital Laboratories
    • 6.5.1. Hospital Laboratories Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.6. Reference Laboratories
    • 6.6.1. Reference Laboratories Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.7. Hospital Emergency Departments
    • 6.7.1. Hospital Emergency Departments Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.8. Urgent Care
    • 6.8.1. Urgent Care Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.9. Others
    • 6.9.1. Others Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

Chapter 7. North America Urinary Tract Infection Testing Market: Regional Analysis

  • 7.1. North America
    • 7.1.1. SWOT Analysis
    • 7.1.2. North America Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)
    • 7.1.3. U.S.
      • 7.1.3.1. Key Country Dynamics
      • 7.1.3.2. Target Disease Prevalence
      • 7.1.3.3. Competitive Scenario
      • 7.1.3.4. Regulatory Framework
      • 7.1.3.5. U.S. Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)
    • 7.1.4. Canada
      • 7.1.4.1. Key Country Dynamics
      • 7.1.4.2. Target Disease Prevalence
      • 7.1.4.3. Competitive Scenario
      • 7.1.4.4. Regulatory Framework
      • 7.1.4.5. Canada Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
    • 8.1.1. QIAGEN
      • 8.1.1.1. Overview
      • 8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.1.3. Product Benchmarking
      • 8.1.1.4. Strategic Initiatives
    • 8.1.2. Accelerate Diagnostics, Inc.
      • 8.1.2.1. Overview
      • 8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.2.3. Product Benchmarking
      • 8.1.2.4. Strategic Initiatives
    • 8.1.3. Bio-Rad Laboratories, Inc.
      • 8.1.3.1. Overview
      • 8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.3.3. Product Benchmarking
      • 8.1.3.4. Strategic Initiatives
    • 8.1.4. F. Hoffmann-La Roche Ltd.
      • 8.1.4.1. Overview
      • 8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.4.3. Product Benchmarking
      • 8.1.4.4. Strategic Initiatives
    • 8.1.5. Danaher Corporation
      • 8.1.5.1. Overview
      • 8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.5.3. Product Benchmarking
      • 8.1.5.4. Strategic Initiatives
    • 8.1.6. Siemens Healthcare GmbH
      • 8.1.6.1. Overview
      • 8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.6.3. Product Benchmarking
      • 8.1.6.4. Strategic Initiatives
    • 8.1.7. Randox Laboratories Ltd.
      • 8.1.7.1. Overview
      • 8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.7.3. Product Benchmarking
      • 8.1.7.4. Strategic Initiatives
    • 8.1.8. Thermo Fisher Scientific, Inc.
      • 8.1.8.1. Overview
      • 8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.8.3. Product Benchmarking
      • 8.1.8.4. Strategic Initiatives
    • 8.1.9. bioMerieux SA
      • 8.1.9.1. Overview
      • 8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.9.3. Product Benchmarking
      • 8.1.9.4. Strategic Initiatives
    • 8.1.10. T2 Biosystems, Inc.
      • 8.1.10.1. Overview
      • 8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.10.3. Product Benchmarking
      • 8.1.10.4. Strategic Initiatives
  • 8.2. Participant's Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Company Market Share Analysis, 2022
  • 8.6. Strategy Mapping
    • 8.6.1. Expansions
    • 8.6.2. Acquisitions
    • 8.6.3. Product/Service Launches
    • 8.6.4. Others

Chapter 9. Conclusion/Analyst Perspective

List of Tables

  • 1. List of Secondary Sources
  • 2. List of Abbreviations
  • 3. North America Urinary Tract Infection Testing Market, By Country, 2018 - 2030 (USD Million)
  • 4. North America Urinary Tract Infection Testing Market, By Type, 2018 - 2030 (USD Million)
  • 5. North America Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6. North America Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 7. U.S. Urinary Tract Infection Testing Market, by Type, 2018 - 2030 (USD Million)
  • 8. U.S. Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 9. U.S. Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 10. Canada Urinary Tract Infection Testing Market, by Type, 2018 - 2030 (USD Million)
  • 11. Canada Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 12. Canada Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

List of Figures

  • 1. Market research process
  • 2. Information procurement
  • 3. Primary research pattern
  • 4. Market research approaches
  • 5. Value chain - based sizing & forecasting
  • 6. Market formulation & validation
  • 7. North America urinary tract infection testing: Market segmentation
  • 8. Market snapshot, 2022
  • 9. Market Trends & Outlook
  • 10. Market driver relevance analysis (current & future impact)
  • 11. Market restraint relevance analysis (current & future impact)
  • 12. Market challenge relevance analysis (current & future impact)
  • 13. SWOT analysis
  • 14. Porter's five forces analysis
  • 15. North America urinary tract infection testing market: Type outlook and key takeaways
  • 16. North America urinary tract infection testing market: Type movement analysis & market share, 2022 & 2030
  • 17. Urethritis market estimates and forecast, 2018 - 2030 (USD Million)
  • 18. Cystitis market estimates and forecast, 2018 - 2030 (USD Million)
  • 19. Pyelonephritis market estimates and forecast, 2018 - 2030 (USD Million)
  • 20. North America urinary tract infection testing market: Product outlook and key takeaways
  • 21. North America urinary tract infection testing market: Product movement analysis & market share, 2022 & 2030
  • 22. Instruments market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 23. Consumables market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 24. North America urinary tract infection testing market: End - use outlook and key takeaways
  • 25. North America urinary tract infection testing market: End - use movement analysis & market share, 2022 & 2030
  • 26. General practitioners market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 27. Urologists market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 28. Urogynecologists market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 29. Hospital laboratories market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 30. Reference laboratories market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 31. Hospital emergency departments market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 32. Urgent care market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 33. Others market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 34. Regional marketplace: key takeaways
  • 35. Regional outlook, 2022 & 2030
  • 36. North America urinary tract infection testing market: region movement analysis.
  • 37. North America urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)
  • 38. U.S. key country dynamics
  • 39. U.S. urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)
  • 40. Canada key country dynamics
  • 41. Canada urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)